Compare Stocks: CNTB, NVCT, MDXG, and FDMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.33 -5.3%	$2.23	$1.23 ▼ $3.82	$146.72M	-0.23	290,196 shs	399,084 shs
FDMT 4D Molecular Therapeutics	$16.10 -3.9%	$11.33	$5.97 ▼ $16.93	$889.36M	2.73	820,623 shs	591,062 shs
MDXG MiMedx Group	$4.32 -2.9%	$4.08	$3.03 ▼ $7.97	$629.68M	1.45	1.31 million shs	703,361 shs
NVCT Nuvectis Pharma	$23.90 +2.4%	$19.02	$5.55 ▼ $29.27	$778.66M	-0.26	165,521 shs	145,110 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	+1.23%	+5.58%	+11.82%	+4.24%	+35.91%
FDMT 4D Molecular Therapeutics	+13.86%	+41.20%	+51.13%	+92.87%	+155.10%
MDXG MiMedx Group	+2.53%	+3.97%	+2.77%	+23.27%	-38.11%
NVCT Nuvectis Pharma	+11.57%	+19.40%	+29.40%	+113.25%	+279.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.33 -5.3%	$2.23	$1.23 ▼ $3.82	$146.72M	-0.23	290,196 shs	399,084 shs
FDMT 4D Molecular Therapeutics	$16.10 -3.9%	$11.33	$5.97 ▼ $16.93	$889.36M	2.73	820,623 shs	591,062 shs
MDXG MiMedx Group	$4.32 -2.9%	$4.08	$3.03 ▼ $7.97	$629.68M	1.45	1.31 million shs	703,361 shs
NVCT Nuvectis Pharma	$23.90 +2.4%	$19.02	$5.55 ▼ $29.27	$778.66M	-0.26	165,521 shs	145,110 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	+1.23%	+5.58%	+11.82%	+4.24%	+35.91%
FDMT 4D Molecular Therapeutics	+13.86%	+41.20%	+51.13%	+92.87%	+155.10%
MDXG MiMedx Group	+2.53%	+3.97%	+2.77%	+23.27%	-38.11%
NVCT Nuvectis Pharma	+11.57%	+19.40%	+29.40%	+113.25%	+279.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.75	Moderate Buy	$7.43	218.82% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	84.01% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.43	95.11% Upside
NVCT Nuvectis Pharma	2.33	Hold	$35.00	46.44% Upside

Current Analyst Ratings Breakdown

Latest CNTB, NVCT, MDXG, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
8/17/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
8/14/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/13/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/5/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/28/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	FDMT 4D Molecular Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
7/17/2026	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$60K	2,445.34	N/A	N/A	$0.43 per share	5.42
FDMT 4D Molecular Therapeutics	$85.21M	10.44	N/A	N/A	$7.38 per share	2.18
MDXG MiMedx Group	$418.63M	1.50	$0.55 per share	7.83	$1.48 per share	2.92
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	N/A
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	N/A
MDXG MiMedx Group	$48.58M	$0.04	108.03	25.41	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)

Latest CNTB, NVCT, MDXG, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
MDXG MiMedx Group	0.07	5.33	4.79
NVCT Nuvectis Pharma	N/A	1.68	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
FDMT 4D Molecular Therapeutics	99.27%
MDXG MiMedx Group	79.15%
NVCT Nuvectis Pharma	96.77%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
FDMT 4D Molecular Therapeutics	7.90%
MDXG MiMedx Group	2.50%
NVCT Nuvectis Pharma	28.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	62.97 million	48.74 million	Optionable
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
NVCT Nuvectis Pharma	8	32.58 million	23.28 million	Not Optionable

CNTB, NVCT, MDXG, and FDMT Headlines

Recent News About These Companies

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

August 19 at 12:36 PM | zacks.com

Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% Higher - What's Next?

August 18 at 12:19 PM | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?

August 14, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

August 9, 2026 | theglobeandmail.com

Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next

August 6, 2026 | tipranks.com

HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma

August 6, 2026 | marketbeat.com

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

August 4, 2026 | finance.yahoo.com

Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS

August 4, 2026 | marketbeat.com

Nuvectis Pharma Target of Unusually Large Options Trading (NASDAQ:NVCT)

August 4, 2026 | marketbeat.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss

August 4, 2026 | marketbeat.com

Nuvectis Pharma Reports Q2 2026 Results, Highlights In-Licensing of Ciprocopan and NXP200 and $115 Million Follow-On Offering

August 4, 2026 | quiverquant.comQ

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

July 29, 2026 | zacks.com

Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday

July 28, 2026 | marketbeat.com

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement ...

July 23, 2026 | markets.businessinsider.com

Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

July 23, 2026 | markets.businessinsider.com

Nuvectis Pharma Announces First Global Approval of Once-Daily Oral Complement Factor B Inhibitor Ciprocopan in China for PNH

July 23, 2026 | quiverquant.comQ

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

July 23, 2026 | globenewswire.com

Nuvectis Pharma (NASDAQ:NVCT) Trading 1.1% Higher - Here's What Happened

July 23, 2026 | marketbeat.com

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

July 14, 2026 | newsfilecorp.comN

Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer

July 9, 2026 | tipranks.com

The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush

July 9, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, NVCT, MDXG, and FDMT Company Descriptions

Connect Biopharma NASDAQ:CNTB

$2.33 -0.13 (-5.28%)

As of 01:33 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

4D Molecular Therapeutics NASDAQ:FDMT

$16.10 -0.66 (-3.94%)

As of 01:33 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

MiMedx Group NASDAQ:MDXG

$4.32 -0.13 (-2.92%)

As of 01:33 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nuvectis Pharma NASDAQ:NVCT

$23.90 +0.57 (+2.44%)

As of 01:32 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, NVCT, MDXG, and FDMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, NVCT, MDXG, and FDMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, NVCT, MDXG, and FDMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, NVCT, MDXG, and FDMT Company Descriptions

Connect Biopharma NASDAQ:CNTB

4D Molecular Therapeutics NASDAQ:FDMT

MiMedx Group NASDAQ:MDXG

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, NVCT, MDXG, and FDMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, NVCT, MDXG, and FDMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, NVCT, MDXG, and FDMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, NVCT, MDXG, and FDMT Company Descriptions

Connect Biopharma NASDAQ:CNTB

4D Molecular Therapeutics NASDAQ:FDMT

MiMedx Group NASDAQ:MDXG

Nuvectis Pharma NASDAQ:NVCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools